Genome Edited iPSCells. Guaranteed.

CRISPR-engineered iPSC cells are enabling a new era in regenerative medicine. Physiologically relevant disease models lead to better discoveries and therapeutics.

Stem Cell Offerings

- Knockout
- Single Nucleotide Variant
- Tags

We offer knockouts, single nucleotide variants, and tag insertions in control or patient-derived iPSC cell lines—available in homozygous or heterozygous clone or pool format.

Tell us about your project at

Synthego.com/SCTM
Cell-Based Therapies for Alveolar Bone and Periodontal Regeneration: Concise Review

FEDERICO MORENO SANCHO, a, b YAGO LEIRA, a, b MARCO ORLANDI, a JACOPO BUTI, a WILLIAM V. GIANNOBILE, c, d FRANCESCO D’AIUTO a

Key Words. Bone and bones • Alveolar ridge preservation • Lateral alveolar ridge augmentation • Sinus augmentation • Periodontal regeneration • Cell- and tissue-based therapy

ABSTRACT

Current regenerative strategies for alveolar bone and periodontal tissues are effective and well adopted. These are mainly based on the use of a combination of synthetic/natural scaffolds and bioactive agents, obviating the incorporation of cells. However, there are some inherent limitations associated with traditional techniques, and we hypothesized that the use of cell-based therapies as part of comprehensive regenerative protocols may help overcome these hurdles to enhance clinical outcomes. We conducted a systematic review of human controlled clinical trials investigating the clinical and/or histological effect of the use of cell-based therapies for alveolar bone and periodontal regeneration and explored the translational potential of the different cell-based strategies identified in the included trials. A total of 16 studies (11 randomized controlled trials, 5 controlled clinical trials) were included for data synthesis and qualitative analysis with meta-analyses performed when appropriate. The results suggest a clinical benefit from the use of cell therapy. Improved outcomes were shown for alveolar ridge preservation, lateral ridge augmentation, and periodontal regeneration. However, there was insufficient evidence to identify best-performing treatment modalities amongst the different cell-based techniques. In light of the clinical and histological outcomes, we identify extraction socket and challenging lateral and vertical bone defects requiring bone block grafts as strong candidates for the adjuvant application of mesenchymal stem cells. Given the complexity, invasiveness, and costs associated with techniques that include “substantial manipulation” of tissues and cells, their additional clinical benefit when compared with “minimal manipulation” must be elucidated in future trials. Stem Cells Translational Medicine 2019;00:1–10

SIGNIFICANCE STATEMENT

Cell-based therapies have the potential to improve outcomes of regenerative treatment in the oral cavity. Extraction sockets and challenging lateral/vertical bone defects requiring bone block grafts are ideal candidates for the adjuvant application of mesenchymal stem cells. The present review showed that there is insufficient evidence to identify best-performing treatment modalities among the different cell-based techniques. Given the complexity, invasiveness and costs associated with the “substantial manipulation” of tissues and cells, the clinical benefit of these techniques when compared with “minimal manipulation” must be elucidated. Further research evaluating the effectiveness of simple, fast, and economical methods for cell harvesting and processing is warranted.

INTRODUCTION

Outcomes in alveolar bone and periodontal regeneration are largely dependent on the biological and the material characteristics of scaffolds and the availability, recruitment and activation of cells and biomolecules in the injured area during healing. A large number of reviews have assessed the outcome of bone regeneration techniques either before or at the time of implant placement and following maxillary sinus augmentation [1–9], including Cochrane systematic reviews [10, 11]. The efficacy of different surgical techniques and biomaterials for periodontal regeneration has also been extensively documented [12, 13]. These therapies are relatively simple and highly cost-effective and, as a result, the use of autologous bone and/or bone substitutes, resorbable and non-resorbable membranes, and different commercially available bioactive products are now routine practice across
the globe. Although proven effective, there is also evidence that
there is large degree of variability on the outcomes achieved.
Failures and high complication rates are common in general dental
practice in larger horizontal and vertical alveolar bone defects
because the augmentation procedures are highly technique-
sensitive. Furthermore, the use of slow resorbing bone biomaterials
may reduce the amounts and quality of newly formed bone in the
augmented area. These issues delay treatment delivery significa-
cantly, especially for the replacement of teeth with dental implants
shortly after tooth extraction. The addition of “smart” bioactive
agents and cell-based approaches to bone scaffolds and mem-
branes may help overcoming some of these limitations. The oppor-
tunity lies on helping surgeons’ activity through advanced but
simple and fast protocols of tissue engineering.

The primary aim of this systematic review is to assess the
efficacy of cell therapies on clinical and histological outcomes for
alveolar bone and periodontal regeneration. We will focus on
the use of these innovative approaches in human clinical studies
investigating specifically ridge preservation, horizontal and verti-
cal alveolar bone augmentation, sinus augmentation techniques,
and periodontal regenerative surgeries. The results will be strati-
fied according to the defect type but also with regard to the
source of mesenchymal stem cells (MSCs) and the techniques for
manipulation of tissue samples and cells. As a secondary out-
come, we aim to investigate the translational potential outside a
hospital/university setting of the different cell-based strategies
identified in the included controlled clinical trials.

METHODS

The protocol was registered on the PROSPERO database: ID
CRD42019121119 (www.crd.york.ac.uk/PROSPERO).

Objectives

• To investigate the evidence for the effect of cell-based ther-
apies as adjuncts to surgery for the regeneration of alveolar
bone/periodontium.
• Critically appraise the validity, methodology, and outcomes
of the included studies.
• Identify and appraise the clinical applicability of emerging cell-

based techniques for alveolar bone/periodontal regeneration.

Types of studies

The review included prospective controlled clinical studies in
human adults (18 years of age or above) evaluating the effect of
surgical treatment with or without the adjunctive use of cell-based
therapies for the treatment of alveolar bone/periodontal defects
assessing changes in alveolar bone dimensions/periodontal clinical
measurements. Secondary outcomes were assessed only for those
studies reporting data on the primary outcomes. A minimum of
6 weeks follow-up post-surgically for alveolar ridge preservation,
3 months follow-up for lateral/vertical ridge, and sinus augmenta-
tion and 12 months for periodontal regeneration studies were
required. Studies were stratified according to the defect model
and each group was analyzed independently: (a) ridge preserva-
tion (ARP); (b) lateral and/or vertical ridge augmentation (GBR);
(c) sinus augmentation (SINUS) d) periodontal regeneration
(PERIO). Studies investigating the use of cell therapies to recon-
struct large defects due to maxillectomies were excluded. Case
reports and/or case series, retrospective clinical studies, and
publications reporting the outcomes of in vitro studies or pre-
clinical (animal) studies only were excluded.

Determination of Outcome Measures

The primary outcome was dependent on the defect model:
postsurgical alterations in the alveolar bone defect size, based
on direct/indirect clinical and/or radiographic measurements
were considered as primary outcomes. See the Supporting
Information for all primary and secondary outcomes selected
according to the defect type.

Search Strategy

A highly sensitive search was conducted. Electronic databases
(MEDLINE, EMBASE, LILACS) were searched using a string of med-
ical subject heading and free-text terms. OpenGrey was searched
for the unpublished, gray literature. The search strategy was first
designed for the MEDLINE database and then modified appropri-
cate for the other databases (see Supporting Information). There
were no language or publication date restrictions. Reference lists
of all studies included for full text screening and previous reviews
were searched for missing records. A manual search for the
period from December 2013 to May 2019 was completed for a
number of scientific journals (see Supporting Information). Fur-
ther details regarding study selection, data extraction and analy-
sis, quality assessment, and the processes followed for data
synthesis can be found in the Supporting Information.

FINDINGS

Search

A total of 5,053 potentially eligible records were returned
from the electronic searches. A further 39 publications were
found through the manual search of the selected journals. Fol-
lowing deletion of duplicates, a total of 4,741 records were avail-
able for initial title/abstract screening, after which the full-text of
74 publications were retrieved. After assessment of the full
papers, a further 56 records were excluded. Therefore, a total of
18 [14–31] publications corresponding to 16 original studies were
included for qualitative analysis. One of the included studies
reported follow-up data from a previously published study [30],
whereas another one was a correction of a previous report [31].
The reason for exclusion of all studies which were not included
following full text assessment was documented (see Supporting
Information). Agreement between examiners after full-text screen-
ing was excellent (Kappa score: 0.896).

There was a total of 11 randomized controlled trials (RCTs)
[16–20, 24–29] and 5 non-randomized controlled original trials
[14, 15, 21–23] included for qualitative analysis. All RCTs incor-
porated a parallel design, whereas CCTs included reports with
either a parallel or a “split mouth” design. Chief characteristics
of the included studies stratified according to defect type can be
found in the Supporting Information. Outcomes were assessed
through an array of different methods. In alveolar bone regenera-
tion studies (ARP, GBR, SINUS), the method of measurement of the
alveolar ridge dimensions (width and/or height) varied between
studies and ranged from direct linear measurements measured
in situ with a probe to linear and volumetric changes assessed
radiographically (Orthopantomogram and Cone Beam Computed
Tomography). Furthermore, analysis of core bone biopsies via his-
tology, microCT, and Synchrotron X-ray Holotomography was also

© 2019 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by STEM CELLS TRANSLATIONAL MEDICINE
Wiley Periodicals, Inc. on behalf of AlphaMed Press
reported. The biopsy assessments mainly quantified new bone formation and relative ratios of new bone, graft remnants, and marrow space. Secondary outcomes frequently reported included complication rates, but only two studies reported other clinically relevant assessments such as the need for additional bone grafting at the time of implant placement and amount of additional bone graft needed [16, 17]. For periodontal regeneration, outcome measures included Clinical Attachment gain (CAL), probing depth reduction (PD), Recession (REC), and defect bone fill (BF) (see Fig. 1).

We identified cell-based therapies according to the type of MSCs harvested and the donor tissue. Seven studies reported the use of bone marrow stem cells (BMSCs) harvested from posterior iliac crest aspiration [16–21, 25, 26], two studies investigated the performance of dental pulp stem cells (DPSCs) harvested from the dental pulp of extracted teeth [14, 28], five of the included publications involved the harvesting of periosteum-derived stem cells (PDSCs) from gingival connective tissue samples [15, 21, 22, 24, 29], one report produced periosteum-derived stem cells (PdSCs) from adipose tissue samples obtained via lipo-aspiration [23]. In line with the definition from the European Medicines Agency Regulation (EC) no 1394/2007 [32], we further subcategorized the techniques in another two groups: (a) “minimal manipulation” of tissues/cells or (b) “substantial manipulation” otherwise (see Table 1). More details about the cell-scaffold combinations and the specifics of the different cell-based harvesting techniques used in all the included publications are presented in the Supporting Information.

Risk of Bias and Methodological Quality

For the ROBIN-I assessment of nonrandomized clinical trials, five of the six studies included were considered to be at a high risk of bias. Among the RCTs assessed with the Cochrane RoB 2.0 tool, two studies showed a low risk of bias, three exhibited some methods which raised some concerns about the risk of bias, and six reported systematic errors in design, adherence or reporting which translated in a high risk of bias. Figure 2 displays the results of the bias and methodological quality assessment for all studies (for further information, see Supporting Information).

Narrative Synthesis and Quantitative Analysis

The reader is referred to the extensive tables in the Supporting Information for a comprehensive summary of clinical, histological, and other relevant outcome data reported in the included studies categorized according to defect type. A brief synthesis is presented below with Forest plots of all meta-analysis carried out presented in Figures 3 and 4.

Alveolar Ridge Preservation

Due to significant differences in study characteristics, it was not possible to complete meta-analysis of effects size for the studies reporting on the use of stem cells for alveolar ridge preservation; a short narrative synthesis is therefore presented.

Of the four original reports included [14–17], two were CCTs [14, 15]. D’Aquino et al. [14] reported statistically significant improvements in radiographic ridge regeneration (%12 months after extraction. Another study by D’Aquino et al. [15] showed that the percentage of resorption of the alveolar ridge was less for the test group than the control group both in the vertical (Mean diff 36.5%, p < .001) and the horizontal (Mean diff 38.33%, p < .001) dimensions 45–90 days after ridge preservation surgery. Another two RCTs reported on the use of BMSCs [16, 17]. In one of the studies, significant differences in percent of radiographic bone height were shown at 6 weeks (Mean diff 23.6% [6.02–41.09], p = .01) but the benefit of the cell-based therapy was lost at 12 weeks (Mean diff 5.4% [−12.11, 22.95], p = .28) [16]. Histological analyses showed that there was no statistically significant increase in the percentage of Bone Tissue Area/Tissue Area at the test sites compared with control at 6 weeks (Mean diff 13.9% [−5.03–33.2], p = .09) and no difference at 12 weeks (Mean diff 0.2% [−19.1% 19.1%], p = .49) [16]. The second RCT reported that at 6 months after tooth extraction, there were no differences between test and control in direct linear measurements of alveolar bone height, but the sites treated with cell therapy showed significantly less horizontal ridge reduction (T: 1.14 mm ± 0.87 mm; C: 2.46 ± 0.4 mm, p = .014) with the test group losing on average 13.61% ± 12.5% and the control group 31.35% ± 11.88% of the original ridge width (p = .006) [17]. The percentage of mineralized bone in the core bone biopsies was similar in both groups (T: 45.47% ± 7.21%, C: 42.87% ± 11.33%, p = .36) [17]. Both studies reported in the number of cases requiring further bone grafting at the time of implant placement and reported a lesser need for additional grafting procedures in cell-based treated sites compared with control.

Guided Bone Regeneration: Lateral Ridge Augmentation

Two studies reporting radiographic horizontal bone width linear measurements outcomes [19, 20] and three [18–20] studies reporting percentage of newly formed bone histologically were included in separate meta-analysis in the guided bone regeneration category. Random effects meta-analysis of the studies reporting alveolar bone width showed a mean extra 1.13 mm alveolar bone gain (95% CI, −1.13, 3.65), 4 to 5.
<table>
<thead>
<tr>
<th>Cells</th>
<th>Source</th>
<th>Harvesting invasiveness</th>
<th>Manipulation (proprietary system)</th>
<th>Defect/studies</th>
<th>Study type /RoB</th>
<th>External resources</th>
<th>Time</th>
<th>Cost</th>
<th>Clinical outcome</th>
<th>Histology outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMSCs</td>
<td>Bone marrow aspirate</td>
<td>Moderate iliac crest punch LA /conscious sedation</td>
<td>Substantial (Replicell)</td>
<td>Kaigler et al. 2013</td>
<td>RCT/SC</td>
<td>Multiple hematologist and GMP lab</td>
<td>&gt;12 days</td>
<td>Very high</td>
<td>Superior/large</td>
<td>Enhanced Similar</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Minimal (BMAC) (harvest Terumo)</td>
<td>Pelegrine et al. 2010</td>
<td>RCT/SC</td>
<td>Hematologist</td>
<td>Hour(s)</td>
<td>High</td>
<td>Superior/modest</td>
<td>Similar</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>GBR / SINUS/</td>
<td>Da Costa et al. 2011</td>
<td>RCT/SC</td>
<td></td>
<td></td>
<td></td>
<td>No difference</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pelegrine et al. 2016</td>
<td>RCT/SC</td>
<td></td>
<td></td>
<td></td>
<td>Superior/large</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Sauerbier et al. 2011</td>
<td>RCT/SC</td>
<td></td>
<td></td>
<td></td>
<td>Similar</td>
<td></td>
</tr>
<tr>
<td>DPSCs</td>
<td>Dental pulp, extracted teeth</td>
<td>High, not readily available</td>
<td>Substantial (Rigenera)</td>
<td>D’Aquino et al. 2009</td>
<td>CCT/low</td>
<td>GMP lab</td>
<td>21 days</td>
<td>Very high</td>
<td>Superior/modest</td>
<td>Enhanced Similar</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Minimal (Rigenera)</td>
<td>Ferrarottiet al. 2018</td>
<td>RCT/low</td>
<td>None</td>
<td>Minutes</td>
<td>Very low</td>
<td>Superior/large</td>
<td>—</td>
</tr>
<tr>
<td>PdSCs</td>
<td>Periosteum, gingival</td>
<td>Very low</td>
<td>Substantial (cell sheets)</td>
<td>D’Aquino 2016</td>
<td>CCT/high</td>
<td>None</td>
<td>Minutes</td>
<td>Very low</td>
<td>Superior/modest</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>connective tissue sample</td>
<td></td>
<td>SINUS/</td>
<td>Ceccarelli et al. 2018</td>
<td>RCT/low</td>
<td></td>
<td></td>
<td></td>
<td>No difference</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Nagata et al. 2012</td>
<td>CCT/high</td>
<td></td>
<td></td>
<td></td>
<td>Superior/large</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Ogawa et al. 2016</td>
<td>CCT/high</td>
<td></td>
<td></td>
<td></td>
<td>Similar</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Yamamiya et al. 2008</td>
<td>RCT/SC</td>
<td></td>
<td></td>
<td></td>
<td>No difference</td>
<td>Enhanced Similar</td>
</tr>
<tr>
<td>PdlSCs</td>
<td>Periodontal ligament,</td>
<td>High, not readily</td>
<td>Substantial (cell sheets)</td>
<td>PERIO/</td>
<td>RCT /low</td>
<td>GMP lab</td>
<td>4-5 weeks</td>
<td>Very high</td>
<td>Superior/modest</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>extracted teeth</td>
<td>available</td>
<td>SINUS/</td>
<td>Chen et al. 2016</td>
<td>RCT /low</td>
<td></td>
<td></td>
<td></td>
<td>No difference</td>
<td>—</td>
</tr>
<tr>
<td>A-SVF</td>
<td>Adipose tissue, liposuction</td>
<td>High, liposuction/GA</td>
<td>Minimal (Celution)</td>
<td>SINUS/</td>
<td>CCT /SC</td>
<td>Plastic surgeon</td>
<td>Hour(s)</td>
<td>High</td>
<td>No difference</td>
<td>Similar</td>
</tr>
<tr>
<td></td>
<td>aspiration</td>
<td></td>
<td></td>
<td>Prins et al. 2016</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No difference</td>
<td></td>
</tr>
</tbody>
</table>

Replicell (Aastrom biosciences) is a commercial automated cell processing unit for isolation of a mixed population of CD90+ MSCs, hematopoietic SCs, inflammatory and endothelial cells (TRCs). Harvest Terumo BCT (Terumo medical do Brasil) is a commercially available system to obtain BMAC including a centrifuge (SmartPrep2) and a processing kit. BMAC system (Harvest Technologies) is a commercially available system to obtain BMAC which includes a harvest BMAC process disposable, 11- and 15-gauge aspiration needles. Rigenera (Human Brain Wave, Italy) is a commercial tissue disaggregator able to filter and select progenitor cells with a size of 50 μm from micrograft samples (adipose tissue, dental pulp, periosteum, etc.). Celution is an automated processing unit for the standardized extraction, washing, and concentration of autologous adipose-derived SVF.

Techniques requiring substantial manipulation are highlighted in gray.

**Abbreviations:** ARP, alveolar ridge preservation; A-SVF, adipose stromal vascular fraction; BMAC, bone marrow aspirate concentrate; BMSCs, bone marrow stem cells; CCT, controlled clinical trial; DPSCs, dental pulp stem cells; GA, general anesthetic; GMP, good manufacturing practice; LA, local anesthetic; LRA, lateral ridge augmentation; mod; moderate; PdSCs, periodontal ligament stem cells; PdlSCs, periosteum derived stem cells; PERIO, periodontal regeneration; RCT, randomized controlled clinical trial; RoB, risk of bias; SC, some concern; SINUS, sinus augmentation; TRCs, tissue repair cells.

*aAt 6 weeks (see discussion).

*bAlveolar thickness loss.

*cAt 6 months.

*dDescribed in text but without quantitative outcome measurement.
6 months post-surgery, favoring cell-based therapies with considerable heterogeneity ($I^2 = 84.9\%$). The combined estimate for the three studies reporting data for percentage of mineralized tissue histologically was $12.76\%$ (95% CI, 2.15, 23.36; $I^2 = 0.0\%$). The three RCTs reported no complications or adverse events.

**Sinus Augmentation**

Three CCTs and three RCTs reported data for radiographic changes in alveolar ridge dimension. However due to discrepancies between studies, only two studies [25, 26] evaluating increase in bone volume in the augmented area were pooled for random-effects meta-analysis. The studies reported contradicting results and, as a result, a nonsignificant mean volumetric bone gain of $0.13\ mm^3$ (95% CI $-0.55, 0.81$) in favor of the stem cell groups with substantial heterogeneity ($I^2 = 58.3\%, p = .122$) was observed. These data are in line with the outcomes of the other four studies with an adequate control groups [21–24] showing no differences in alveolar ridge vertical or volumetric gain between cell-based approaches and positive controls without cell endorsement (see Supporting Information).

Histologically, two studies [23, 26] reported similar findings: there were no significant differences between groups with or without cell therapy for new bone formation. Furthermore, two studies [23, 25] reported a nonsignificant higher bone volume fraction within the newly regenerated bone as assessed by micro-CT analysis. The publications showed no complications or significant adverse events with the exception of one study that reported one injury of the inferior alveolar nerve when harvesting autogenous bone and two other infections of the bone donor site.

**Periodontal Regeneration**

For studies aiming to achieve periodontal regeneration, one of the RCTs did not report clinical measurements beyond 3 months and did not report the standard deviations of the differences in radiographic bone fill at 12 months postop [27]. For this reason, two studies [28, 29] assessing CAL, PD, REC, and BF 12 months after surgery were included in separate meta-analysis. The combined estimate for the two studies showed significant benefits of using cell therapy for periodontal regeneration in terms of CAL (1.33 mm; 95% CI, 0.47, 2.19; $I^2 = 0.0\%$) and radiographic BF (2 mm; 95% CI, 1.41, 2.58; $I^2 = 0.3\%$) with no observed heterogeneity and a nonsignificant improvement in PD (0.91 mm; 95% CI,
−0.05, 1.88; \(I^2 = 50.2\%\), and REC (0.36 mm; 95% CI, −0.30, 1.02; \(I^2 = 18.1\%\)). This positive effect is further illustrated by one of the studies reporting CAL gain as a % of the original defect, showing 83.5% (\(\div C6\) 31.7) defect resolution in cell-grafted sites compared with 55.0% (\(\div C6\) 21.9) in control sites [29]. Finally, the other study included in the meta-analysis demonstrated a significantly higher percentage of sites showing CAL gain >4 mm (73.3% vs. 28.6%) and less sites with probing pocket depths >6 mm (0% vs. 14.3%) for the defects treated with cell techniques [28].

**Clinical Applicability: Beyond the Hospital/University Setting**

There were virtually no complications and no severe adverse events across all of the included studies in all the different defect categories, demonstrating the safety of this treatment modality. Although there were insufficient data to draw any conclusions regarding best cell-based treatment strategies, an appraisal of the clinical applicability of the different techniques identified through the systematic search is warranted. Our assessment of the different techniques will appraise aspects which may be relevant for widespread adoption later on the translational pathway. We hope this will help identifying techniques which may be prioritized in future research.

The studies [14–17] assessing changes after grafting of the alveolar ridge following tooth extraction suggest that ARP should be a targeted intervention to demonstrate the clinical potential of cell-based therapy for alveolar bone regeneration. The clinical strategy after a tooth is extracted most often involves the decision to place a dental implant with a type 1/type 2 placement [33] leaving the ridge to heal undisturbed. The placement of slow-resorbing bone substitutes unnecessarily lengthens the waiting period before a dental implant can be inserted [9]. In the current review, limited data suggests that significant improvements may be obtained on reducing ridge resorption and improving bone quality within the first 6 weeks of healing when progenitor cells are endorsed in fast-resorbing collagen sponges and grafted on “extraction socket” defects. The additional benefit provided by cell therapy may justify the associated costs of (some of) the techniques by reducing the need of major grafting while shortening treatment times. Similar conclusions may be drawn for lateral ridge augmentation of large

**INTERPRETATION**

**Overall Quality, Strength, and Consistency of Evidence**

The low number of included studies does not come as a surprise given that only recently the application of cell-based therapies for regeneration of alveolar bone and periodontal tissues has been reported. We focused our research question around RCTs and CCTs which could contribute clinical outcome measures and not only histology analysis. For this reason, the secondary histology outcomes reported in this review were limited due to many studies reporting only histology analyses being excluded.

The CCTs included in this review were considered to be at a high risk of bias [14, 15, 21–23]. On the other hand, the RCTs comprised a somehow less biased data set with 5 of the 11 original reports showing low levels of bias [16, 25, 27–29]. Furthermore, there was a great degree of variability on study design as well as many different cell populations and scaffold combinations, making the test and control groups not homogenous as a whole. The overall estimates from the meta-analysis, albeit they represent the best-available evidence, should be interpreted with caution.
horizontal defects. On the other hand, sinus augmentation procedures seem less appropriate for this technique [21–26]. A marginal or no effect was reported both for clinical and histology outcomes. This is perhaps related to the fact that the maxillary sinus defect is, by nature, a spontaneous-healing model [34]. Although excellent outcomes were shown in the periodontal regeneration studies, the outcomes in the control groups cannot be considered comparable to what is expected from gold standard therapy according to previous research. Therefore, further research comparing this technique to Guided Tissue Regeneration or well-proven bioactive agents such as Emdogain® is needed to elucidate whether there is merit on pursuing this application further. Both in sinus augmentation surgery and periodontal regeneration, it is evident that a wide range of techniques have proven to be largely successful on achieving predictable and highly successful outcomes, and, hence, it may be difficult to ever find a large enough “perceived clinical benefit” which could justify the cost and operational needs of cell-based therapies. An exception maybe the use of cost-effective “mini-mal” manipulation techniques such as the one described by Ferraroti et al. [28].

The regeneration of tissues depends mainly on three key players: scaffolds, cells, and biomolecules coming together to orchestrate a series of spatial-temporal events which result in a pattern of healing that resembles the original components, structure, and function of the lost tissues. There were significant differences between the techniques appraised in this review on the use of scaffolds and “biologics.” For instance, there was a wide range of different scaffolds which were used as “carriers” for the cells. When the studies are stratified according to defect type, it becomes apparent that the scaffolds were selected according to the biomechanical and biological requirements of the defects which were being reconstructed and not for their ability to improve cell attachment and/or behavior. For this reason, we will focus the discussion on the cell harvesting and manipulation steps.

We based our “clinical applicability” appraisal on domains like those described in Roger’s diffusion of innovation theory [35] (see Table 1). This theory has been previously tailored and implemented for analysis of key elements influencing the widespread adoption of new technologies/techniques in healthcare [36] and dentistry [37]. Stem cells can be categorized in four different groups depending on their source [38]: (a) embryonic tissues, (b) fetal tissues, (c) postnatal tissues, and (d) induced pluripotent stem (iPS) cells. Embryonic stem cells have the highest proliferative rate and are able to differentiate into any of the three embryonic germ layers (ectoderm, mesoderm, and endoderm) and can therefore be a source for almost all cell types within the human body. However, their consideration for use is affected by ethical issues since their isolation involves the use of human embryos [38]. In the future, the use of iPS cells [39] would circumvent these ethical concerns. Another alternative currently available is the recruitment of postnatal stem cells, more widely known as MSCs derived broadly from nearly every organ and tissue. Compared with embryonic stem cells and iPS cells, MSCs have restricted differentiation potential and proliferative rates, showing great variability depending on the tissue source [38]. Although the term stem cell therapy is widely used to describe the use of any of the cell populations above or even to also include therapies using cells further committed in the differentiation pathway, it seems more appropriate to use more focused terms which provide a better description of their differentiation potential (i.e., tissue-specific cell therapy). We identified therapies involving five distinct cell populations: BMSCs obtained from BMA [16–20, 26], DPSCs from the dental pulp of extracted...
teeth [14, 28], PdSCs [15, 21, 22, 24, 29] from gingival connective tissue samples, PdSCs [27] from extracted teeth, and A-SVF [23] from adipose tissue.

We consider the invasiveness of the harvesting procedure as one of the factors potentially affecting adoption. The techniques involving DPSCs and PdSCs harvesting require the extraction of a tooth. This invasive procedure would only be appropriate in cases where teeth are already scheduled, limiting its applicability. The harvesting of A-SVF requires a liposuction under general anesthesia and is therefore considered highly invasive. Bone marrow aspirates were carried out under local anesthesia and, in some cases, conscious sedation and were rated as moderately invasive. The less invasive technique was the harvesting of gingival connective tissue from intra-oral sources. The clear advantage of this technique is that tissues are readily available. Besides their invasiveness, the need of a BMA or liposuction adds an additional layer of complexity due to the need to contact and organize specialists outside the dental office while also adding significant costs.

After harvesting, the cells were either “minimally” or “substantially” modified before application in the surgical site. The rationale for cell expansion is based on the fact that only a small fraction of the cells within the donor tissues are characterized as MSCs. Billions of cells can be generated from as little as 1 ml of bone marrow aspirate following ex vivo expansion [38, 40]. On the other hand, despite low cell yields, “minimal manipulation” of the source tissue will include cells and matrix proteins other than MSCs which may also play a key role for tissue regeneration. Furthermore, there is no known threshold above or below in which cell yield is relevant for improving clinical outcomes. It has recently been suggested that we should “move away from autograft-based therapy” and that “the preferred therapeutic strategy moving forward is the use of ex vivo expanded MSC preparations rather than whole bone marrow aspirate transplantation or autografts that contain limited MSC numbers diluted within a heterogeneous population of blood/immune cells [38].”

ex vivo cell expansion is a complex process that requires significant investment in terms of time, resources, and capital, and there is currently no evidence to support an additional clinical benefit compared with “minimal” manipulation of cells, at least for the management of the alveolar bone defects most commonly found in day to day practice. It is also evident, albeit from only the limited number of clinical trials available, that techniques requiring “minimal” manipulation of tissues and cells have shown clinical and histology benefits in all the defect models reviewed, casting doubts on the “absolute need” for cell expansion. Furthermore, cell survival in vivo following transplantation may be short-lived [41]. It has been suggested that MSCs effects go beyond their innate ability to survive and differentiate into tissue forming cells but lies within their ability to “secrete bioactive factors that are immunomodulatory and trophic [42].” The use of cellular therapies may act in the clinical context by one of either two broad mechanisms: (a) Cell Replacement—whereby transplanted (generally autologous cells) successfully are accepted to the local host site and then begin the process of tissue regeneration of the local defect; and/or (b) Cell Empowerment—mechanism whereby cells (either autologous or allogeneic) display a more transient effect in the local area to release factors that may promote the regenerative response [43]. Whether or not ex vivo cell expansion is a prerequisite for the success of cell-based therapies is an important question, one should be answered through future well-designed randomized controlled clinical trials.

The time that lapsed from cell harvesting to application in “substantially manipulated” therapies ranged from 12 days to over 6 weeks [14, 16, 21, 22, 25, 27, 29]. Furthermore, cell expansion requires GMP grade laboratories and personnel. A publication of a report of three cases using these techniques showed that the GMP level laboratory preparatory costs to the Finnish healthcare system were the equivalent of £8,900 per patient [44]. In addition to these elevated expenses, the need of significant external resources and the high complexity of the interventions make these therapies impractical outside the hospital/university settings. Among the “minimally manipulated” techniques, A-SVF obtained through processing of adipose samples using an automated processing unit (Celution®, Cytori Therapeutics, USA) is the most invasive, expensive, and complex alternative followed by the use of BMAC obtained through processing with a commercially available system (Harvest Terumo®, BCT, Terumo Medical do Brasil, Brazil) after iliac crest aspiration. A viable alternative may be the use of a commercially available tissue disaggregator (Rigenera®, Human Brain Wave, Italy) able to filter progenitor cells with a size of 50 μm from micrograft tissue samples (i.e., adipose tissue, dental pulp, periosteum) [45]. The Rigenera system presented clinical data in four studies investigating all defect models covered in this review. Using this device, DPSCs and PdSCs were obtained from dental pulp tissue and gingival connective tissue samples showing promising results.

Outstanding Questions

Based on a limited number of studies, cell-based therapies have the potential to improve outcomes of regenerative treatment for the reconstruction of alveolar bone and periodontal tissues. We identified extraction socket defects and challenging lateral and vertical bone defects requiring bone block grafts as ideal candidates for the adjuvant application of MSCs. This review showed that there is insufficient evidence to identify best-performing treatment modalities among the different cell-based techniques described in the included publications. This research synthesis has also highlighted a high risk of bias in most of the studies and the need for well-designed randomized clinical controlled trials including the gold standard of treatment as a positive control. Given the complexity, invasiveness and costs associated with techniques which include “substantial manipulation” of tissues and cells, their clinical benefit when compared with “minimal manipulation” must be elucidated in future trials. Further research evaluating the clinical effect and cost-effectiveness of simple, fast, and economical methods for cell harvesting and processing is warranted.

Author Contributions

F.M.S.: protocol design, publication screening, data abstraction, data analysis, interpretation of results, writing of the manuscript; Y.L.: protocol design, publication screening, data abstraction, data analysis, interpretation of results, reviewing the manuscript; M.O.: protocol design, data analysis, interpretation of results, review of the manuscript; J.B.: protocol design, data analysis, interpretation of results, review of the manuscript; W.V.G.: interpretation of results, review of the manuscript; F. D.: interpretation of results, review of the manuscript.

© 2019 The Authors. Stem Cells Translational Medicine published by Wiley Periodicals, Inc. on behalf of AlphaMed Press
REFERENCES


41. de Windt TS, Vonk LA, Saris DBF. Response to: Mesenchymal Stem Cells: Time
See www.StemCellsTM.com for supporting information available online.